A Practical Investigation into Achieving Bio-Plausibility in Evo-Devo Neural Microcircuits Feasible in an FPGA

Many researchers has conjectured, argued, or in some cases demonstrated, that bio-plausibility can bring about emergent properties such as adaptability, scalability, fault-tolerance, self-repair, reliability, and autonomy to bio-inspired intelligent systems. Evolutionary-developmental (evo-devo) spiking neural networks are a very bio-plausible mixture of such bio-inspired intelligent systems that have been proposed and studied by a few researchers. However, the general trend is that the complexity and thus the computational cost grow with the bio-plausibility of the system. FPGAs (Field- Programmable Gate Arrays) have been used and proved to be one of the flexible and cost efficient hardware platforms for research' and development of such evo-devo systems. However, mapping a bio-plausible evo-devo spiking neural network to an FPGA is a daunting task full of different constraints and trade-offs that makes it, if not infeasible, very challenging. This thesis explores the challenges, trade-offs, constraints, practical issues, and some possible approaches in achieving bio-plausibility in creating evolutionary developmental spiking neural microcircuits in an FPGA through a practical investigation along with a series of case studies. In this study, the system performance, cost, reliability, scalability, availability, and design and testing time and complexity are defined as measures for feasibility of a system and structural accuracy and consistency with the current knowledge in biology as measures for bio-plausibility. Investigation of the challenges starts with the hardware platform selection and then neuron, cortex, and evo-devo models and integration of these models into a whole bio-inspired intelligent system are examined one by one. For further practical investigation, a new PLAQIF Digital Neuron model, a novel Cortex model, and a new multicellular LGRN evo-devo model are designed, implemented and tested as case studies. Results and their implications for the researchers, designers of such systems, and FPGA manufacturers are discussed and concluded in form of general trends, trade-offs, suggestions, and recommendations

Laparoscopic repair of iatrogenic long ureteral injury

Introduction: Transection of the ureter in laparoscopic retroperitoneal lymph node dissection (RPLND) is a rare iatrogenic complication. Its repair is possible by end-to-end anastomosis when the defect is short, but if there is a long defect, laparoscopic repair is a challenge. Methods: A 30-year-old man underwent modified RPLND of a clinically stage-A mixed germ cell of the left testis. While cutting the gonadal vein, 1.5 cm of the ureter was transected 2 cm below the renal pelvis and clipped by one of our residents. The injury was diagnosed immediately. After the completion of the modified RPLND, the clips were removed and a 20-mm defect of the ureter was seen precluding anastomosis. The kidney was dissected and pulled down 35 mm. The lower pole of the kidney was then fixed to the psoas muscle by a 2-0 vicryl, making anastomosis possible after an 8-mm spatulation of both sides. Anastomosis was done over a stent by interrupted sutures using 4-0 vicryl. Results: Leakage was 400 mL at the first postoperative day and ceased at the 4th day. On the control excretion urography, the kidney function was normal and a fullness of the caliceal system was seen. Conclusion: Long defect of the ureter that may occur in laparoscopic urological surgeries could be manageable laparoscopically using methods for shortening of the interval such as relocation of the kidney. Thus, a same approach as open surgeries can yield acceptable results in laparoscopic surgeries

Análise da precificação de carbono para geração de eletricidade a partir de termelétrica a gás natural e energia solar fotovoltaica: estudo de caso para escolas públicas do Distrito Federal.

Governo do Estado do Par

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

A more bio-plausible approach to the evolutionary inference of finite state machines

With resemblance of finite-state machines to some biological mechanisms in cells and numerous applications of finite automata in different fields, this paper uses analogies and metaphors to introduce an element of bio-plausibility to evolutionary grammatical inference. Inference of a finite-state machine that generalizes well over unseen input-output examples is an NP-complete problem. Heuristic algorithms exist to minimize the size of an FSM keeping it consistent with all the input-output sequences. However, their performance dramatically degrades in presence of noise in the training set. Evolutionary algorithms perform better for noisy data sets but they do not scale well and their performance drops as size or complexity of the target machine grows. Here, inspired by a biological perspective, an evolutionary algorithm with a novel representation and a new fitness function for inference of Moore finite-state machines of limited size is proposed and compared with one of the latest evolutionary techniques. Copyright 2007 ACM